¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷ : 2022-11-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷ : 2022-11-10
±³À°ÀÏÀÚ : 2022-11-10
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ¿ùµå Å©¸®½ºÅ»·ë(ÇÏÀ̺긮µå Çмú´ëȸ)  
±³À°ÁÖÁ¦ : (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 110,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 07:50~08:40 Overcoming Resistance after 3rd Generation TKI Treatment in EGFR Mutant Non-Small Cell Lung Cancer  Suresh S. Ramalingam(Emory Univ., USA) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 08:40~08:50 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 08:50~09:10 Extent of Lymph Node Dissection during Sublobar Resection  Yoohwa Hwang(Seoul National Univ) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:10~09:30 Sublobar Resection in Compromized Patients  Jeong Su Cho(Sungkyunkwan Univ.) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:30~09:50 Additional Management (for Incomplete or Local Recurrence) after Sublobar Resection  Seong Yong Park(Sungkyunkwan Univ.) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:50~10:10 Japan Clinical Oncology Group Studies about Sublobar Resection  Hisashi Saji(St. Marianna Univ., Japan) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:10~10:30 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:30~11:00 Antibody-Drug Conjugates: A Promising Novel Therapeutic Approach in Lung Cancer  David Planchard(Gustave Roussy, France) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:00~11:20 EGFR-TK Degradation by PROTACs  Sumi Lee(J2HBiotech) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:20~11:50 LAG 3 Immunotherapy in Lung Cancer  Scott Nicholas Gettinger(Yale Univ. Medical Center, USA) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:50~12:00 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 12:00~12:40 Spotlighting the New 3rd generation EGFR TKI, Lazertinib: Updated Clinical Study Results & Real World Outcomes  Sun Min Lim(Yonsei Univ) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 12:40~13:00 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 13:00~13:30 Expanding the Benefits of Immunotherapy for Cancer: Combine and Conquer  Dan G. Duda(Harvard Medical School, USA) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 13:30~14:05 Atezolizumab-Grab: Beyond the PD-L1 Blockade in Cancers  Keehoon Jung(Seoul National Univ) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 14:05~14:40 Combination of Two Distinct Subsets of Peripheral Blood CD8+ T Cells from Patients with Non-Small Cell Lung Cancer Predicts Response Outcome to Immune Checkpoint Blockade Therapy  Jae Ho Cho(Chonnam National Univ.) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 14:40~15:00 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 15:00~15:30 Chest Imaging of Treatment-Related Pneumonitis  Hyae Young Kim(National Cancer Center) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 15:30~16:00 How to Deal with Treatment-Related Pneumonitis  Sun Min Lim(Yonsei Univ.) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:00~16:40 Optimal Management of Radiation and Drug Related Pneumonitis in Unresectable Stage III Non-Small Cell Lung Cancer Patients  William N. William(UT MD Anderson Cancer Center, USA) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:40~16:50 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:50~17:40 Pembrolizumab Combination Strategies in Lung Cancer: Present and Future  Bin Zhao(MSD Global Clinical Research) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷ : 2022-11-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦34Â÷ Ãß°èÇмú´ëȸ(1ÀÏÂ÷) : 2022-11-11
´ÙÀ½±Û °æ»ó±¹¸³´ëÇб³º´¿ø ¼­ºÎ°æ³² À̺ñÀÎÈÄ°ú Áý´ãȸ ¿¬¼ö±³À°(³»½Ã°æ ±Í¼ö¼úÀÇ ½Ç·Ê) : 2022-11-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20850 ±¤ÁÖ 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-22 0 7 2024-05-27
20849 ¼­¿ï ´ëÇÑÃé´ãµµÇÐȸ [¿Â¶óÀÎ] Pancreato-Biliary Summer School 2024 (PB-SS) : 2024-06-22 0 12 2024-05-27
20848 ¼­¿ï Á¦26Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : °áÇÙ°ú ºñ°áÇÙÇ×»ê±Õ ÆóÁúȯÀÇ ÃÖ½ÅÁö°ß : 2024-06-22 0 13 2024-05-27
20847 ¼­¿ï Á¦3ȸ Severance Orthopaedic Review(¼¼ºê¶õ½º ±Ù°ñ°Ý ¿¬¼ö°­ÁÂ) : 2024-06-22 0 6 2024-05-27
20846 ¼­¿ï (¿Â¶óÀÎ)2024³â ¼­´ë¹®±¸ÀÇ»çȸ ¿Â¶óÀÎÇмú´ëȸ : 2024-06-22 0 7 2024-05-27
20845 ¼­¿ï ´ëÇѳúÀüÁõÇÐȸ 29rd KOREAN EPILEPSY CONGRESS (2024 KEC) 2ÀÏÂ÷ : 2024-06-22 0 14 2024-05-27
20844 ´ë±¸ 2024³â Á¦ 23ȸ ´ëÇѵΰ³¾È¸é¼ºÇü¿Ü°úÇÐȸ Ãá°è½ÉÆ÷Áö¾ö : 2024-06-22 0 4 2024-05-27
20843 ¼­¿ï µ¿ÀÛ±¸ÀÇ»çȸ ÀÇÇÐ ¿¬¼ö±³À°(¸¸¼ºÁúȯ, Å»¸ð¿Í ÇǺΰü¸®, »ý¼ºÇü AI Æ®·»µå¿Í ÀÇ·á, ÀÇ·áºÐÀï) : 2024-06-22 0 16 2024-05-27
20842 ¼­¿ï (¿Â¶óÀÎ) °øȲ¹üºÒ¾ÈÀå¾Ö Ä¡·áÀÇ ½ÉÃþÀû Á¢±Ù : 2024-06-22 0 10 2024-05-27
20841 °æ±â 2024³â ´ëÇѳëÀκñ´¢ÀÇÇÐȸ Á¦7Â÷ Á¤±âÇмú´ëȸ : 2024-06-22 0 7 2024-05-27
20840 ¼­¿ï (¿Â¶óÀÎ) Á¦34Â÷ ´ëÇѼҾÆÀÓ»ó¸é¿ªÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-22 0 12 2024-05-27
20839 ´ë±¸ 2024 ´ë±¸±¤¿ª½ÃÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-22 0 19 2024-05-27
20838 ¼­¿ï »ï¼º¼­¿ïº´¿ø The 21th SMC STROKE SYMPOSIUM, 2024 : 2024-06-22 0 6 2024-05-27
20837 ±¤ÁÖ 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-06-21 0 10 2024-05-27
20836 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 2±â(2ÀÏÂ÷) : 2024-06-21 0 5 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷